Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Merck
Express Scripts
Medtronic

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206352

See Plans and Pricing

« Back to Dashboard

NDA 206352 describes REYATAZ, which is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from four suppliers. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the REYATAZ profile page.

The generic ingredient in REYATAZ is atazanavir sulfate. There are twenty-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atazanavir sulfate profile page.
Summary for 206352
Tradename:REYATAZ
Applicant:Bristol Myers Squibb
Ingredient:atazanavir sulfate
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206352
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REYATAZ atazanavir sulfate POWDER;ORAL 206352 NDA E.R. Squibb & Sons, L.L.C. 0003-3638 0003-3638-10 30 PACKET in 1 CARTON (0003-3638-10) > 1 POWDER in 1 PACKET

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrengthEQ 50MG BASE/PACKET
Approval Date:Jun 2, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 24, 2019
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Patent:  Start TrialPatent Expiration:Jun 21, 2019Product Flag?Substance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Express Scripts
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.